GT201200150A - Método para el tratamiento de trastornos proliferativos y otras condiciones patológicas mediadas por la actividad de cinasa de brc-abl,c-kit, ddr1, ddr2 o pdgf-r - Google Patents
Método para el tratamiento de trastornos proliferativos y otras condiciones patológicas mediadas por la actividad de cinasa de brc-abl,c-kit, ddr1, ddr2 o pdgf-rInfo
- Publication number
- GT201200150A GT201200150A GT201200150A GT201200150A GT201200150A GT 201200150 A GT201200150 A GT 201200150A GT 201200150 A GT201200150 A GT 201200150A GT 201200150 A GT201200150 A GT 201200150A GT 201200150 A GT201200150 A GT 201200150A
- Authority
- GT
- Guatemala
- Prior art keywords
- ddr1
- pdgf
- treatment
- proliferative disorders
- kit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE AUN RÉGIMEN A UN RÉGIMEN PARA LA ADMINISTRACIÓN DE UNA PIRIMIDIL-AMINO-BENZAMIDA DE LA FÓRMULA I, PARA EL TRATAMIENTO DE TRASTORNOS PROLIFERATIVOS, EN PARTICULAR TUMORES SÓLIDOS O LÍQUIDOS Y OTRAS CONDICIONES PATOLÓGICAS MEDIADAS POR LA ONCOPROTEÍNA DEL BCR-ABL, EL RECEPTOR DE CINASA DE TIROSINA TRANSMEMBRANA CELULAR C-KIT O LA ACTIVIDAD DE CINANA DE DDR1 (RECEPTRO DE DOMINIO DE DISCOIDINA 1) O PDGF-R.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26181209P | 2009-11-17 | 2009-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201200150A true GT201200150A (es) | 2014-08-11 |
Family
ID=43513643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201200150A GT201200150A (es) | 2009-11-17 | 2012-05-17 | Método para el tratamiento de trastornos proliferativos y otras condiciones patológicas mediadas por la actividad de cinasa de brc-abl,c-kit, ddr1, ddr2 o pdgf-r |
Country Status (37)
Country | Link |
---|---|
US (1) | US9061029B2 (es) |
EP (1) | EP2501384B2 (es) |
JP (2) | JP5829615B2 (es) |
KR (1) | KR101743315B1 (es) |
CN (1) | CN102612368B (es) |
AR (1) | AR079029A1 (es) |
AU (1) | AU2010322102B2 (es) |
BR (1) | BR112012011693A2 (es) |
CA (1) | CA2779490C (es) |
CL (1) | CL2012001270A1 (es) |
CO (1) | CO6551690A2 (es) |
DK (1) | DK2501384T4 (es) |
EC (1) | ECSP12011903A (es) |
ES (1) | ES2572128T5 (es) |
FI (1) | FI2501384T4 (es) |
GT (1) | GT201200150A (es) |
HK (1) | HK1169950A1 (es) |
HR (1) | HRP20160472T4 (es) |
HU (1) | HUE027307T2 (es) |
IL (1) | IL219727A (es) |
JO (1) | JO3634B1 (es) |
MA (1) | MA33738B1 (es) |
ME (1) | ME02413B (es) |
MX (1) | MX2012005694A (es) |
MY (1) | MY169956A (es) |
NZ (1) | NZ599968A (es) |
PE (1) | PE20121476A1 (es) |
PL (1) | PL2501384T5 (es) |
RS (1) | RS54747B2 (es) |
RU (1) | RU2625835C2 (es) |
SG (1) | SG10201501169VA (es) |
SI (1) | SI2501384T2 (es) |
SM (1) | SMT201600143B (es) |
TN (1) | TN2012000206A1 (es) |
TW (1) | TWI498116B (es) |
WO (1) | WO2011062927A1 (es) |
ZA (1) | ZA201203328B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013068836A1 (en) | 2011-11-07 | 2013-05-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis |
AR090835A1 (es) | 2012-04-24 | 2014-12-10 | Chugai Pharmaceutical Co Ltd | Derivados de quinazolindiona |
WO2013161851A1 (ja) | 2012-04-24 | 2013-10-31 | 中外製薬株式会社 | ベンズアミド誘導体 |
AU2013256227B2 (en) | 2012-05-02 | 2017-06-15 | Georgetown University | Treating neural disease with tyrosine kinase inhibitors |
SI2861579T1 (en) * | 2012-05-15 | 2018-05-31 | Novartis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
US9561245B2 (en) | 2012-09-06 | 2017-02-07 | The Board Of Regents Of The University Of Texas System | Combination treatments for melanoma |
US20140080772A1 (en) * | 2012-09-06 | 2014-03-20 | The Board Of Regents Of The University Of Texas System | Treatments for melanoma |
US9572828B2 (en) | 2013-07-18 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
EP3061749B1 (en) | 2013-10-23 | 2019-02-27 | Chugai Seiyaku Kabushiki Kaisha | Quinazolinone and isoquinolinone derivative |
MX2018000677A (es) * | 2015-08-31 | 2018-05-07 | Toray Industries | Derivado de urea y uso del mismo. |
CN108103186B (zh) * | 2018-02-28 | 2021-07-02 | 固安博健生物技术有限公司 | 诊断类风湿性关节炎和骨关节炎的分子标志物 |
JP7409696B2 (ja) | 2018-06-15 | 2024-01-09 | ハンダ ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤の塩およびその組成物 |
WO2020144650A1 (en) * | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of prostate cancer |
CA3168680A1 (en) | 2020-01-31 | 2021-08-05 | Nanocopoeia, Llc | Amorphous nilotinib microparticles and uses thereof |
CA3181361A1 (en) | 2020-04-30 | 2021-11-04 | Nanocopoeia, Llc | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100343237C (zh) | 2002-06-28 | 2007-10-17 | 日本新药株式会社 | 酰胺衍生物及医药品 |
GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
NZ538405A (en) | 2002-08-01 | 2007-12-21 | Aesgen Inc | Improved treatment of cancer with glutamine and carbohydrate |
EP1879585B1 (en) * | 2005-05-02 | 2013-04-17 | Novartis AG | Use of pyrimidylamimobenzamide derivatives for the treatment of systemic mastocytosis |
SA06270147B1 (ar) | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين |
GT200600316A (es) | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
GT200600315A (es) | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
EP1923053A1 (en) | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
KR100925559B1 (ko) | 2007-10-26 | 2009-11-05 | 한국과학기술연구원 | 악티노마이신 d를 유효성분으로 하는 ddr과 콜라겐결합 저해제 |
-
2010
- 2010-11-14 JO JOP/2010/0396A patent/JO3634B1/ar active
- 2010-11-15 AR ARP100104212A patent/AR079029A1/es not_active Application Discontinuation
- 2010-11-16 TW TW099139425A patent/TWI498116B/zh active
- 2010-11-17 WO PCT/US2010/056926 patent/WO2011062927A1/en active Application Filing
- 2010-11-17 KR KR1020127012603A patent/KR101743315B1/ko active IP Right Grant
- 2010-11-17 ME MEP-2016-89A patent/ME02413B/me unknown
- 2010-11-17 PE PE2012000667A patent/PE20121476A1/es not_active Application Discontinuation
- 2010-11-17 US US13/509,626 patent/US9061029B2/en active Active
- 2010-11-17 NZ NZ599968A patent/NZ599968A/en unknown
- 2010-11-17 ES ES10781781T patent/ES2572128T5/es active Active
- 2010-11-17 CA CA2779490A patent/CA2779490C/en active Active
- 2010-11-17 MX MX2012005694A patent/MX2012005694A/es active IP Right Grant
- 2010-11-17 HU HUE10781781A patent/HUE027307T2/hu unknown
- 2010-11-17 SG SG10201501169VA patent/SG10201501169VA/en unknown
- 2010-11-17 EP EP10781781.9A patent/EP2501384B2/en active Active
- 2010-11-17 FI FIEP10781781.9T patent/FI2501384T4/fi active
- 2010-11-17 BR BR112012011693A patent/BR112012011693A2/pt not_active Application Discontinuation
- 2010-11-17 AU AU2010322102A patent/AU2010322102B2/en active Active
- 2010-11-17 SI SI201031172T patent/SI2501384T2/sl unknown
- 2010-11-17 DK DK10781781.9T patent/DK2501384T4/da active
- 2010-11-17 MY MYPI2012001993A patent/MY169956A/en unknown
- 2010-11-17 RS RS20160303A patent/RS54747B2/sr unknown
- 2010-11-17 HR HRP20160472TT patent/HRP20160472T4/hr unknown
- 2010-11-17 PL PL10781781.9T patent/PL2501384T5/pl unknown
- 2010-11-17 JP JP2012539982A patent/JP5829615B2/ja active Active
- 2010-11-17 CN CN201080051819.0A patent/CN102612368B/zh active Active
- 2010-11-17 RU RU2012124811A patent/RU2625835C2/ru active
-
2012
- 2012-05-07 TN TNP2012000206A patent/TN2012000206A1/en unknown
- 2012-05-08 ZA ZA2012/03328A patent/ZA201203328B/en unknown
- 2012-05-10 IL IL219727A patent/IL219727A/en active IP Right Grant
- 2012-05-11 MA MA34855A patent/MA33738B1/fr unknown
- 2012-05-16 CL CL2012001270A patent/CL2012001270A1/es unknown
- 2012-05-16 EC ECSP12011903 patent/ECSP12011903A/es unknown
- 2012-05-17 CO CO12081907A patent/CO6551690A2/es not_active Application Discontinuation
- 2012-05-17 GT GT201200150A patent/GT201200150A/es unknown
- 2012-10-26 HK HK12110734.6A patent/HK1169950A1/zh unknown
-
2015
- 2015-04-28 JP JP2015091857A patent/JP2015180636A/ja active Pending
-
2016
- 2016-05-23 SM SM201600143T patent/SMT201600143B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201200150A (es) | Método para el tratamiento de trastornos proliferativos y otras condiciones patológicas mediadas por la actividad de cinasa de brc-abl,c-kit, ddr1, ddr2 o pdgf-r | |
CR20110029A (es) | Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina | |
UA111075C2 (uk) | Триазолопіридинові сполуки як інгібітори кінази рім | |
MX353308B (es) | Derivados fosforosos como inhibidores de cinasa. | |
BR112013002220A2 (pt) | derivado de ftalazinona cetona, método de prepração do mesmo, e uso farmacêutico do mesmo | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
UY32882A (es) | (heteroarilmetil) tiohidantoínas sustituidas | |
UY35249A (es) | Inhibidores del receptor del factor de crecimiento de fibroblastos | |
EA201490891A1 (ru) | Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ | |
MY167245A (en) | Compounds and compositions as c-kit kinase inhibitors | |
GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
CO6170360A2 (es) | Derivados de pirimidinil - piridazinona | |
NI201100052A (es) | Derivados de picolinamida como inhibidores de cinasa. | |
DOP2013000027A (es) | Derivados de tetrahidro-pirido-pirimidina | |
UY32125A (es) | Compuestos novedosos como ligandos de receptores de canabinoides | |
BR112012027197A2 (pt) | combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas | |
UA112795C2 (uk) | Біциклічні піразинонові похідні | |
UY32331A (es) | Compuestos novedosos como ligandos de receptores de canabinoides | |
TN2012000150A1 (en) | Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity | |
EA201270280A1 (ru) | Соединения пиримидина в качестве ингибиторов при лечении туберкулеза | |
UY32214A (es) | Agonistas del receptor s1p para el tratamiento de malaria cerebral | |
CO6260091A2 (es) | Derivados de iminopiridina y su uso | |
CO6351779A2 (es) | Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos | |
PH12016500092A1 (en) | New azabenzimidazole derivatives | |
CL2009001112A1 (es) | Compuestos derivados de cinolin-3-carboxamida, inhibidores de la quinasa csf-1r; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer. |